

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 10 2002

In re Application of:

Elizabeth Moyer et al.

Application No.: 09/393,590

Filed: 09/09/1999

For: STABLE LIQUID FORMULATIONS OF  
BOTULINUM TOXIN

Examiner: Devi, S.

Group No.: 1645

RECEIVED

JUN 14 2002

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILEDCertificate of Mailing (37 C.F.R. § 1.8(a)):

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231.

Date: June 3, 2002

By: Amy Knowles

Assistant Commissioner for Patents  
Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Dear Sir:

1. Transmitted herewith is:

- ☒ Information Disclosure Statement
- ☒ PTO Form 1449
- ☒ Copies of publications listed on the PTO Form 1449
- ☐ English translation of foreign language reference(s)
- ☐ No copies of publications cited on the PTO Form 1449 are being provided as this application claims continuation status to application Serial No. \_\_\_\_\_ and copies of the listed publications were provided in the parent application.

- ☒ Copy of foreign examination report
- ☒ English translation of foreign examination report

2. ☒ This Information Disclosure Statement is filed after the events noted in paragraph 2, but before either:

- ☒ Final action under 37 CFR 1.113, or
- ☒ Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97 (c) also enclosed is:

- ☐ Fee under 37 CFR 1.17(p) in the amount of \$240.00; or
- ☒ Statement as stated below.

3. Statement. The undersigned states:

- ☒ Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or

4. Fees

- ☐ Check in the amount of \$ \_\_\_\_\_ is attached.  
☐ Please charge Deposit Account No. 01-2707 in the amount of \$240.00.  
☐ No fee is required.  
☒ The Commissioner is hereby authorized to charge any underpayment or credit any overpayment of the following fees associated with this communication to Deposit Account No. 01-2707:  
☒ Any patent application processing fees under 37 CFR 1.17.

Date: June 3, 2002

Reg. No. 41,490  
Tel. No. (650) 866-2773

Customer No.: 21835

Respectfully submitted,

Leslie J. Boley  
SIGNATURE OF PRACTITIONER

Leslie J. Boley  
Elan Pharmaceuticals Inc.  
800 Gateway Boulevard  
South San Francisco, CA 94080